ReAlta Life Sciences has secured $40 million in an oversubscribed financing round, strengthening its balance sheet as it pushes its lead therapy for hypoxic ischemic encephalopathy, or HIE, through mid-stage development. The Virginia-based clinical-stage biotechnology company said the new capital will fund major clinical and regulatory steps for pegtarazimod, a drug candidate aimed at reducing inflammation-linked brain injury in newborns. With this latest raise, ReAlta said it has now brought in more than $150 million since the company was formed.
Funding Supports Next Development Milestones
According to the company, the proceeds will be used to move pegtarazimod through a series of near-term milestones, including completion of the ongoing Phase 2 STAR trial, release of top-line data, and an End-of-Phase 2 meeting with the U.S. Food and Drug Administration. Those events are seen as important checkpoints in determining the therapy’s clinical potential and regulatory path. The financing also signals continued investor support for ReAlta’s strategy of pursuing first-in-class treatments for severe inflammatory disorders.
Chief executive Howard Berman said the fundraising reflects strong belief in the candidate’s potential to address a major unmet need in neonatal medicine. He framed HIE as a condition that leaves thousands of infants each year with serious brain injury despite the absence of any approved drug therapy. Berman added that pegtarazimod is designed to intervene earlier in the inflammatory process by targeting both complement activation and neutrophil-driven inflammation, which he described as central drivers of injury in HIE.
A Drug Candidate Targeting Inflammation at Its Source
Pegtarazimod, also known as RLS-0071, is a 15-amino-acid peptide and serves as ReAlta’s lead development program. The company says the therapy is intended to block multiple inflammatory pathways, including complement activation at C1, myeloperoxidase activity, and neutrophil extracellular trap formation. By acting on both humoral and cellular inflammation, ReAlta is positioning the candidate as a differentiated approach for diseases in which immune dysregulation causes tissue damage.
The company said pegtarazimod has shown favorable tolerability and encouraging clinical signals in studies involving healthy volunteers and patients with serious inflammatory conditions. ReAlta also noted that the therapy has received FDA Orphan Drug and Fast Track designations for HIE, as well as Orphan Drug designation from the European Medicines Agency. Those designations can help accelerate development and review, while also underscoring the severity of the condition being targeted.
Focus on Hypoxic Ischemic Encephalopathy
HIE is a serious form of neonatal brain injury caused by reduced oxygen and blood flow to the brain during or near the time of birth. The condition remains a leading cause of infant death and long-term neurological complications, including cerebral palsy, epilepsy, and cognitive impairment. Although therapeutic hypothermia is the current standard of care, it offers limited benefit and does not directly address the inflammatory damage that continues after the initial oxygen-deprivation event.
That treatment gap is a major part of the commercial and medical rationale behind ReAlta’s program. The company argues that a therapy capable of improving neurological outcomes in affected newborns could address a significant unmet need while opening a substantial market opportunity. President and chief operating officer Kia Motesharei said the fresh capital will allow ReAlta to pursue those goals with a focused strategy centered on clinical execution and value-creating milestones.
STAR Trial Progress and Strategic Outlook
The Phase 2 STAR trial is currently enrolling newborns with moderate or severe HIE who are undergoing therapeutic hypothermia, according to the company. ReAlta said the randomized, double-blind, placebo-controlled study is being conducted in two stages and is active across 13 neonatal intensive care units in the United States. The trial will be closely watched by investors and clinicians alike because its results could shape the future direction of the program and determine whether the therapy can advance toward later-stage studies.
Motesharei said the company is not aiming for an incremental improvement, but for a broader shift in how HIE is treated in newborns. That language reflects the ambition biotech companies often use around first-in-class therapies, though clinical data will ultimately determine whether that promise can be realized. For now, ReAlta’s latest financing gives it the resources to reach the next set of proof points at a moment when interest remains high in therapies that address severe conditions with limited treatment options.
ReAlta’s latest fundraising marks an important step in its effort to develop what could become the first drug treatment specifically targeting inflammatory injury in HIE. The company now enters a critical phase in which clinical readouts and regulatory discussions will test whether pegtarazimod can translate scientific promise into a viable medical breakthrough. Until those data arrive, the oversubscribed round stands as a clear sign that investors see meaningful potential in both the program and the market it aims to serve.